Exceptional Early-Stage Investigators Push the Boundaries of Translational Research
By Brandon Levy
Thursday, December 5, 2019
Online and print publications are constantly touting momentous discoveries by superstar scientists like CRISPR-Cas9 co-discover Jennifer Doudna or the IRP’s own Kevin Hall, who changed the way we think about weight loss. It can be easy to forget that today’s biomedical pioneers were once young researchers toiling to establish themselves in the competitive environment of modern science.
Each year, a small, exceptionally promising group of scientific up-and-comers become Lasker Clinical Research Scholars through a highly competitive program jointly funded by the NIH and the Albert and Mary Lasker Foundation. The program presents early-stage physician-scientists with the opportunity to carry out independent clinical research at the NIH for five to ten years. The 2019 class of Lasker Scholars consists of five extremely talented researchers who are now beginning a critical new phase in their careers. Let’s meet them.
Understanding Social and Behavioral Research in the IRP
By Christopher Marcum
Tuesday, December 3, 2019
The NIH IRP is world-renowned for its high-risk, high-reward biomedical research. While the NIH may be best known for its clinical and biomedical research on topics from cancer to allergies to addiction, IRP investigators have also produced a rich body of work conducted in the area of social and behavioral research (SBR). In this post, I will describe how SBR furthers the NIH’s goals of improving human health with some examples of the excellent work done by SBR investigators in the IRP.
By Brandon Levy
Tuesday, December 11, 2018
The more scientists have learned about the community of benign bacteria inside our bodies, known as the microbiome, the more effort they have put into recruiting it in the fight against disease. What’s more, scientists occasionally discover that treatments long thought to work completely independently of our native microbes also relieve symptoms by interacting with them. New IRP research into the most commonly used medication for type 2 diabetes has led to just such a revelation by demonstrating that its benefits stem in part from its ability to kill off a particular species of bacteria in the human digestive tract.
By Brandon Levy
Tuesday, June 19, 2018
Hundreds of scientific studies have established that obesity often leads to severe health problems and cuts short many lives. Nevertheless, a significant number of obese people remain healthy despite their excess weight. A new IRP study has now identified a possible molecular marker that distinguishes obese but healthy individuals from those whose weight has negatively affected their health.
